Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Phase II TANGO Trial Was Targeting Anti-Tau For Early Disease
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
You may also be interested in...
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.
While many other approaches have failed, Ionis and Biogen hope their novel oligonucleotide can stop toxic tau tangles forming in the brain.
Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.